Drug Profile

IP 2018 - Initiator Pharma

Alternative Names: IP-2018 - Initiator Pharma

Latest Information Update: 07 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Saniona
Developer Initiator Pharma
Class Antidepressants; Erectile dysfunction therapies
Mechanism of Action Neurotransmitter uptake inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Erectile dysfunction

Most Recent Events

07 Oct 2022 IP 2018 is still in phase II trial for Erectile dysfunction in United Kingdom(PO, Liquid) (NCT04686916) (Initiator pharmaceutical company pipeline)
26 Jun 2020 Phase-II clinical trials in Erectile dysfunction in United Kingdom (PO, Liquid) (EudraCT2020-000469-18) (NCT04686916)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com